Table 3 Comparison between the changes in CQAP parameters and risk reduction rate over 3Â years
| Â | AS | NAS | Risk reduction rate in AS compared to NAS | P-value |
|---|---|---|---|---|
Clinical practice parameters | ||||
 PFT conduction rate |  + 14.6% |  + 12.1% | − 2.4% |  < 0.001 |
 Inhaled LAMA prescription rate |  + 14.9% |  + 54.5% |  + 25.8% |  < 0.001 |
 Inhaled LABA prescription rate |  + 8.1% |  + 4.6% | − 3.5% |  < 0.001 |
 ICS prescription rate | − 2.4% | − 2.2% |  + 0.2% |  < 0.001 |
 SABA prescription rate | − 41.9% |  + 4.4% |  + 44.6% |  < 0.001 |
Prognosis | ||||
 Frequency of admission for COPD | − 3.6% |  + 22.0% |  + 21.2% |  < 0.001 |
 All-cause mortality in the next year | − 0.3% |  + 65.2% |  + 40.7% |  < 0.001 |